These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 29890208

  • 21. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
    Tu X, Kahila MM, Zhou Q, Yu J, Kalari KR, Wang L, Harmsen WS, Yuan J, Boughey JC, Goetz MP, Sarkaria JN, Lou Z, Mutter RW.
    Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399
    [Abstract] [Full Text] [Related]

  • 22. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y, Xi Q, Chen Y, Wang J, Peng P, Xia S, Yu S.
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [Abstract] [Full Text] [Related]

  • 23. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
    Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E, Stewart G, Brown J, Lau A, Pratt G, Parry H, Taylor M, Moss P, Hillmen P, Stankovic T.
    Blood; 2016 Feb 04; 127(5):582-95. PubMed ID: 26563132
    [Abstract] [Full Text] [Related]

  • 24. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Jette NR, Radhamani S, Arthur G, Ye R, Goutam S, Bolyos A, Petersen LF, Bose P, Bebb DG, Lees-Miller SP.
    Br J Cancer; 2019 Oct 04; 121(7):600-610. PubMed ID: 31481733
    [Abstract] [Full Text] [Related]

  • 25. IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma.
    Qiao Y, Zhang C, Li A, Wang D, Luo Z, Ping Y, Zhou B, Liu S, Li H, Yue D, Zhang Z, Chen X, Shen Z, Lian J, Li Y, Wang S, Li F, Huang L, Wang L, Zhang B, Yu J, Qin Z, Zhang Y.
    Oncogene; 2018 Feb 15; 37(7):873-883. PubMed ID: 29059160
    [Abstract] [Full Text] [Related]

  • 26. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
    Biskup E, Naym DG, Gniadecki R.
    J Dermatol Sci; 2016 Dec 15; 84(3):239-247. PubMed ID: 27743911
    [Abstract] [Full Text] [Related]

  • 27. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
    Jiang HG, Chen P, Su JY, Wu M, Qian H, Wang Y, Li J.
    J Cell Physiol; 2017 Dec 15; 232(12):3433-3443. PubMed ID: 28075014
    [Abstract] [Full Text] [Related]

  • 28. ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status.
    Laroche-Clary A, Chaire V, Verbeke S, Algéo MP, Malykh A, Le Loarer F, Italiano A.
    Sci Rep; 2020 May 04; 10(1):7488. PubMed ID: 32366852
    [Abstract] [Full Text] [Related]

  • 29. Downregulation of ALDH5A1 suppresses cisplatin resistance in esophageal squamous cell carcinoma by regulating ferroptosis signaling pathways.
    Song K, Ma C, Maswikiti EP, Gu B, Wang B, Wang N, Jiang P, Chen H.
    Mol Carcinog; 2024 Oct 04; 63(10):1892-1906. PubMed ID: 38923019
    [Abstract] [Full Text] [Related]

  • 30. Radiation induces NORAD expression to promote ESCC radiotherapy resistance via EEPD1/ATR/Chk1 signalling and by inhibiting pri-miR-199a1 processing and the exosomal transfer of miR-199a-5p.
    Sun Y, Wang J, Ma Y, Li J, Sun X, Zhao X, Shi X, Hu Y, Qu F, Zhang X.
    J Exp Clin Cancer Res; 2021 Sep 29; 40(1):306. PubMed ID: 34587992
    [Abstract] [Full Text] [Related]

  • 31. Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
    Jackson CB, Noorbakhsh SI, Sundaram RK, Kalathil AN, Ganesa S, Jia L, Breslin H, Burgenske DM, Gilad O, Sarkaria JN, Bindra RS.
    Cancer Res; 2019 Sep 01; 79(17):4331-4338. PubMed ID: 31273061
    [Abstract] [Full Text] [Related]

  • 32. Chloroquine reverses chemoresistance via upregulation of p21WAF1/CIP1 and autophagy inhibition in ovarian cancer.
    Hwang JR, Kim WY, Cho YJ, Ryu JY, Choi JJ, Jeong SY, Kim MS, Kim JH, Paik ES, Lee YY, Han HD, Lee JW.
    Cell Death Dis; 2020 Dec 04; 11(12):1034. PubMed ID: 33277461
    [Abstract] [Full Text] [Related]

  • 33. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
    Teng PN, Bateman NW, Darcy KM, Hamilton CA, Maxwell GL, Bakkenist CJ, Conrads TP.
    Gynecol Oncol; 2015 Mar 04; 136(3):554-61. PubMed ID: 25560806
    [Abstract] [Full Text] [Related]

  • 34. Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
    Nam AR, Jin MH, Bang JH, Oh KS, Seo HR, Oh DY, Bang YJ.
    Cancer Res Treat; 2020 Jul 04; 52(3):945-956. PubMed ID: 32311864
    [Abstract] [Full Text] [Related]

  • 35. Cancer-associated fibroblasts mediated chemoresistance by a FOXO1/TGFβ1 signaling loop in esophageal squamous cell carcinoma.
    Zhang H, Xie C, Yue J, Jiang Z, Zhou R, Xie R, Wang Y, Wu S.
    Mol Carcinog; 2017 Mar 04; 56(3):1150-1163. PubMed ID: 27769097
    [Abstract] [Full Text] [Related]

  • 36. The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells.
    Moolmuang B, Ruchirawat M.
    J Pharm Pharmacol; 2021 Mar 01; 73(1):40-51. PubMed ID: 33791808
    [Abstract] [Full Text] [Related]

  • 37. Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.
    Knegtel R, Charrier JD, Durrant S, Davis C, O'Donnell M, Storck P, MacCormick S, Kay D, Pinder J, Virani A, Twin H, Griffiths M, Reaper P, Littlewood P, Young S, Golec J, Pollard J.
    J Med Chem; 2019 Jun 13; 62(11):5547-5561. PubMed ID: 31074988
    [Abstract] [Full Text] [Related]

  • 38. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma.
    Wu M, Wang Y, Yang D, Gong Y, Rao F, Liu R, Danna Y, Li J, Fan J, Chen J, Zhang W, Zhan Q.
    EBioMedicine; 2019 Mar 13; 41():244-255. PubMed ID: 30876762
    [Abstract] [Full Text] [Related]

  • 39. VE-822 Enhanced Cisplatin Chemotherapy Effects on Head and Neck Squamous Cell Carcinoma Drug-resistant Cells.
    Chen T, Yang F, Dai X, Yu Y, Sun Y, Wu X, Li R, Zhou Q.
    Curr Cancer Drug Targets; 2023 Mar 13; 23(6):482-495. PubMed ID: 36748213
    [Abstract] [Full Text] [Related]

  • 40. Entinostat reverses cisplatin resistance in esophageal squamous cell carcinoma via down-regulation of multidrug resistance gene 1.
    Huang XP, Li X, Situ MY, Huang LY, Wang JY, He TC, Yan QH, Xie XY, Zhang YJ, Gao YH, Li YH, Rong TH, Wang MR, Cai QQ, Fu JH.
    Cancer Lett; 2018 Feb 01; 414():294-300. PubMed ID: 29107111
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.